Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, a leader in synthetic biotechnology, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 3:30 pm ET. This event aims to showcase Amyris's innovations in sustainable consumption through its Lab-to-Market™ platform, which combines advanced technology with biotechnology. Interested parties can access a live webcast and replay on the company's Investor Relations page.
Amyris, a synthetic biotechnology company (Nasdaq: AMRS), announced a conference call on November 22, 2021, at 6:00 a.m. PT to discuss its recent financing activity. CEO John Melo and CFO Han Kieftenbeld will lead the discussion. The call is open to all, with a live webcast available at investors.amyris.com. A recording will be available for 90 days. Amyris focuses on sustainable ingredients in Clean Health & Beauty and Flavors & Fragrances markets, utilizing its Lab-to-Market™ platform and innovative technologies.
Amyris, a synthetic biotechnology leader, has successfully closed an offering of $690 million in 1.50% convertible senior notes due 2026. The offering, completed on November 15, 2021, will bear interest payable semiannually, commencing May 15, 2022. The notes are convertible into shares of Amyris' common stock at an initial conversion price of approximately $10.75 per share. Proceeds will be used for various corporate purposes, including repaying existing debt and potential acquisitions. The offering may affect future share dilution.
Amyris, based in Emeryville, California, has priced $600 million in aggregate principal amount of 1.50% convertible senior notes due 2026, up from an initial $400 million offering. The notes will mature on November 15, 2026, with an annual interest rate of 1.50%, payable semiannually. The initial conversion price is set at approximately $10.75 per share, reflecting a 35% premium to the closing price of $7.96 on November 9, 2021. Amyris intends to use around $70.5 million for capped call transactions and $51 million to repay senior debt, with remaining proceeds aimed at general corporate purposes.
Amyris, Inc. (Nasdaq: AMRS) announced its intention to offer $400 million in convertible senior notes due 2026, subject to market conditions. The offering will be conducted via private placement to qualified institutional buyers under Rule 144A. An additional $60 million may also be purchased by initial buyers. Proceeds will be used for capped call transactions, repaying existing debts, and general corporate purposes. The notes are convertible under specific conditions, and their redemption can occur from November 20, 2024. The announcement is not an offer to sell or solicit securities.
Amyris (AMRS) reported strong Q3 2021 results, achieving record underlying revenue of $48 million, a 40% year-over-year increase, and record consumer revenue of $23 million, up 89%. Despite facing global supply chain challenges impacting raw material supplies and freight costs, the company launched four new consumer brands and completed three acquisitions. Amyris expects full-year revenue to reach $330 - $370 million, doubling 2020 figures. Key future projects include a joint venture for a COVID-19 vaccine and the construction of a new ingredients plant in Brazil.
Amyris, Inc. (Nasdaq: AMRS) has formed a 50:50 joint venture with ImmunityBio, Inc. (Nasdaq: IBRX) to commercialize a next-generation COVID-19 vaccine. The binding term sheet has been signed, with a definitive agreement expected soon. ImmunityBio will handle vaccine manufacturing post-human trials in South Africa, while Amyris provides its RNA technology and sustainable squalene. The venture aims to deliver one billion doses in 2022, targeting vaccine access in developing countries and addressing supply chain challenges.
Amyris, a leader in synthetic biotechnology, will announce its Q3 financial results for the period ending September 30, 2021, after market close on November 8, 2021. A conference call featuring CEO John Melo and other executives will follow at 1:30 PM PT (4:30 PM ET) to discuss the results and provide updates. Amyris is recognized for its sustainable ingredients in Clean Health, Beauty, and Wellness, serving over 300 million consumers through various brands like Biossance and Purecane.
Amyris, Inc. (Nasdaq: AMRS) announced a licensing agreement for the Onyx genome engineering platform from Inscripta on October 5, 2021. This collaboration aims to enhance the development of sustainable ingredients through automated gene editing, which is expected to improve efficiency and reduce timelines for product innovation. Amyris has successfully commercialized 13 sustainable ingredients used in over 20,000 products, reaching over 300 million consumers, demonstrating a strong market demand for sustainable solutions.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology, successfully held its fourth investor webinar titled "Lab-to-Market, Delivering Disruptive Health and Beauty Products" on September 28, 2021, attended by over 350 investors. CEO John Melo presented Amyris' mission to transition to sustainable consumption, emphasizing technological advancements and manufacturing excellence that support their Lab-to-Market operating system. The session highlighted key products like Hemisqualane for haircare and a THC-free CBG formulated with Squalane for skin conditions. Presentation materials are available on their investor website.
